Evidence map›Paper›PMID 12740431›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2003

Identification of receptors for pig endogenous retrovirus.

Thomas A Ericsson, Yasuhiro Takeuchi, Christian Templin, Gary Quinn, Shelli F Farhadian, James C Wood, Beth A Oldmixon, Kristen M Suling, Jennifer K Ishii, Yoshinori Kitagawa and 4 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03695939 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

An Open-label Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe and Extensive Deep-Partial and Full-Thickness Burn Wounds

TypeinterventionalSponsorXenoTherapeutics, Inc.Ran2019 to 2023Enrolled25ConditionsDeep Full-thickness Burn Injury (Disorder)ArmsrealSKIN (skin xenotransplant), Human Cadaver Allograft
NCT06223269 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase III Open-Label, Multicenter, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Mixed-Depth, Full-Thickness Burn Wounds as an Alternative to Autografting

TypeinterventionalSponsorXenoTherapeutics, Inc.Ran2024 to 2026Enrolled50ConditionsBurns Degree Third, Burn (Disorder), Burn Degree Second, Thermal BurnArmsSkin Xenotransplant, Autograft(ing)
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 151 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Infectious Diseases and Clinical Xenotransplantation.Emerging infectious diseases · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021
    Review
  16. Infection in xenotransplantation: opportunities and challenges.Current opinion in organ transplantation · 2019
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Thomas A EricssonImmerge BioTherapeutics, Inc., 300 Technology Square, Cambridge, MA 02139, USA.
Yasuhiro Takeuchi
Christian Templin
Gary Quinn
Shelli F Farhadian
James C Wood
Beth A Oldmixon
Kristen M Suling
Jennifer K Ishii
Yoshinori Kitagawa
Takayuki Miyazawa
Daniel R Salomon
Robin A Weiss
Clive Patience
University College London · GBScripps Research Institute · USOsaka University · JP

Funding

XENOGENEIC INFECTION RISK WITH ISLET TRANSPLANTATIONR01AI045494 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI SALOMON, DANIEL RENE · 1999 to 2002
$876k
NIAID NIH HHS R01 AI045494NIAID NIH HHS R01 AI45494
6 · The paper itself

Abstract

Xenotransplantation of porcine tissues has the potential to treat a wide variety of major health problems including organ failure and diabetes. Balanced against the potential benefits of xenotransplantation, however, is the risk of human infection with a porcine microorganism. In particular, the transmission of porcine endogenous retrovirus (PERV) is a major concern [Chapman, L. E. & Bloom, E. T. (2001) J. Am. Med. Assoc. 285, 2304-2306]. Here we report the identification of two, sequence-related, human proteins that act as receptors for PERV-A, encoded by genes located on chromosomes 8 and 17. We also describe homologs from baboon and porcine cells that also are active as receptors. Conversely, activity could not be demonstrated with a syntenic murine receptor homolog. Sequence analysis indicates that PERV-A receptors [human PERV-A receptor (HuPAR)-1, HuPAR-2, baboon PERV-A receptor 2, and porcine PERV-A receptor] are multiple membrane-spanning proteins similar to receptors for other gammaretroviruses. Expression is widespread in human tissues including peripheral blood mononuclear cells, but their biological functions are unknown. The identification of the PERV-A receptors opens avenues of research necessary for a more complete assessment of the retroviral risks of pig to human xenotransplantation.

Indexed as

Amino Acid SequenceAnimalsBase SequenceDNA PrimersEndogenous RetrovirusesHeLa CellsHumansMiceMolecular Sequence DataReceptors, VirusSequence Homology, Amino AcidSwineDNA PrimersReceptors, Virus

Identifiers

PMID12740431
PMCPMC164520
OpenAlexW2120922919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.